Every material Form 8-K CITIUS ONCOLOGY, INC. has filed with the SEC since October 23, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Citius Oncology announced health-related quality of life results from pivotal Study 302 of LYMPHIR, presented at the EORTC-CLTG 2026 Annual Meeting in Berlin. The company reported sustained quality of life improvements among responders, but the analyses were descriptive, the study was not designed or powered for these outcomes, and the results are not included in the LYMPHIR Prescribing Information. The filing contains no revenue, earnings, or guidance figures, so it provides clinical data without a stated financial effect on shareholders.
Study 302 data were presented October 8-10, 2026, at the EORTC-CLTG 2026 Annual Meeting in Berlin; the press release is dated November 4, 2026.
Among responders (n=25) in the primary analysis set (n=69), mean change in Skindex-29 Total Score ranged from -5.38 to -13.69 points, where lower scores indicate better quality of life.
Among 41 heavily pretreated patients with baseline itch of 20 mm or greater, 13 (32%) achieved a clinically meaningful improvement.
No formal statistical comparisons were performed, and the results are not included in the LYMPHIR Prescribing Information.
Citius Oncology reported preliminary, unaudited LYMPHIR unit sales to U.S. wholesalers of 792 units for the fiscal fourth quarter ended September 30, 2026, up 120% from 360 units in the prior quarter. The figures are not audited, and the company will report full fiscal fourth quarter and fiscal 2026 results in December 2026 in its Form 10-K, so the final numbers may differ.
Wholesaler units purchased were 792 for the three months ended September 30, 2026, versus 360 for the three months ended June 30, 2026.
LYMPHIR vials ordered by prescribing centers from wholesalers were 950, compared with 926 for the fiscal third quarter.
54 institutions had ordered LYMPHIR as of the release date, up from 44 as of August 14, 2026. The company's revenue is recognized on wholesaler sales, net of estimated gross-to-net adjustments.
Citius Oncology received a Nasdaq notice on October 19, 2026 granting it until April 19, 2027 to evidence compliance with the $1.00 per share minimum bid price rule for continued Nasdaq Capital Market listing. The company's stock will keep trading under the symbol CTOR for now, but if it does not regain compliance by that date, Nasdaq will notify it that the stock is subject to delisting, and the company may appeal to a hearings panel.
Nasdaq extension runs through April 19, 2027 for compliance with the $1.00 per share bid price requirement.
Compliance requires a closing bid price of $1.00 or more for at least ten consecutive business days before April 19, 2027.
The company says it is evaluating options for regaining compliance and cannot assure it will do so.
The extension has no immediate effect on the CTOR listing on The Nasdaq Capital Market.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CITIUS ONCOLOGY, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →